* Precision BioSciences Inc DTIL.OQ reported a quarterly
adjusted loss of $2.25 per share for the quarter ended
September 30, lower than the same quarter last year, when the
company reported EPS of $-2.10. The mean expectation of
six analysts for the quarter was for a loss of $1.92 per share.
Wall Street expected results to range from $-3.27 to -79 cents
per share.
* Revenue fell 95.6% to $576.00 thousand from a year ago;
analysts
expected $6.36 million.
* Precision BioSciences Inc's reported EPS for the quarter
was a
loss of $2.25.
* The company reported a quarterly loss of $16.43 million.
* Precision BioSciences Inc shares had risen by 0.7% this
quarter and lost 17.6% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 7.9%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Precision
BioSciences Inc is $30.00
This summary was machine generated from LSEG data November 4 at
03:19 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -1.92 -2.25 Missed
Jun. 30 2024 -1.50 4.67 Beat
Mar. 31 2024 -1.91 -0.35 Beat
Dec. 31 2023 -2.05 -4.06 Missed